Novel PET Tracers: Added Value for Endocrine Disorders

Overview

Journal Endocrine

Specialty Endocrinology

Date 2019 Mar 16

PMID 30875057

Citations 6

Authors

Sebastien Bergeret

Judith Charbit

Catherine Ansquer

Geraldine Bera

Philippe Chanson

Charlotte Lussey-Lepoutre

Affiliations

Soon will be listed here.

Abstract

Nuclear medicine has been implicated in the diagnosis and treatment of endocrine disorders for several decades. With recent development of PET tracers, functional imaging now plays a major role in endocrine tumors enabling with high performance to their localization, characterization, and staging. Besides F-FDG, which may be used in the management and follow-up of endocrine tumors, new tracers have emerged, such as F-DOPA for neuroendocrine tumors (NETs) (medullary thyroid carcinoma, pheochromocytomas and paragangliomas and well-differentiated NETs originating from the midgut) and F-Choline in the field of primary hyperparathyroidism. Moreover, some peptides such as somatostatin analogs can also be used for peptide receptor radionuclide therapy. In this context, Gallium-68 labeled somatostatin analogs (Ga-SSA) can help to tailor therapeutic choices and follow the response to treatment in the so-called "theranostic" approach. This review emphasizes the usefulness of these three novel PET tracers (F-Choline, F-FDOPA, and Ga-SSA) for primary hyperparathyroidism and neuroendocrine tumors.

Citing Articles

The historical progression of positron emission tomography research in neuroendocrinology.

Bini J Front Neuroendocrinol. 2023; 70:101081.

PMID: 37423505 PMC: 10530506. DOI: 10.1016/j.yfrne.2023.101081.

Non-FDG PET/CT in Diagnostic Oncology: a pictorial review.

Giammarile F, Castellucci P, Dierckx R, Estrada Lobato E, Farsad M, Hustinx R Eur J Hybrid Imaging. 2021; 3(1):20.

PMID: 34191163 PMC: 8218094. DOI: 10.1186/s41824-019-0066-2.

Solitary late metastasis of primary renal cell carcinoid tumor to the extraocular muscles imaged with indium-111 octreotide.

Dempsey P, OConnell M, Bolster F World J Nucl Med. 2021; 20(1):99-101.

PMID: 33850497 PMC: 8034783. DOI: 10.4103/wjnm.WJNM_28_20.

The role of F-FCH PET/CT in patients with uremic hyperparathyroidism compared with Tc-sestaMIBI SPECT/CT and ultrasonography.

Xue Y, Li W, Xia Z, Lei C, Cao Y, Wang Z EJNMMI Res. 2019; 9(1):118.

PMID: 31879808 PMC: 6933043. DOI: 10.1186/s13550-019-0583-9.

A side-by-side evaluation of [F]FDOPA enantiomers for non-invasive detection of neuroendocrine tumors by positron emission tomography.

Narayan A, Yan Y, Lisok A, Brummet M, Pomper M, Lesniak W Oncotarget. 2019; 10(56):5731-5744.

PMID: 31645896 PMC: 6791383. DOI: 10.18632/oncotarget.27184.

References

Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E . 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med. 2001; 28(1):64-71. DOI: 10.1007/s002590000404. View

Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K . A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism:.... Medicine (Baltimore). 2015; 94(41):e1701. PMC: 4616781. DOI: 10.1097/MD.0000000000001701. View

Ambrosini V, Castellucci P, Rubello D, Nanni C, Musto A, Allegri V . 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun. 2009; 30(4):281-6. DOI: 10.1097/MNM.0b013e32832999c1. View

Balogova S, Talbot J, Nataf V, Michaud L, Huchet V, Kerrou K . 18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. Eur J Nucl Med Mol Imaging. 2013; 40(6):943-66. PMC: 3644207. DOI: 10.1007/s00259-013-2342-x. View

Janssen I, Chen C, Taieb D, Patronas N, Millo C, Adams K . 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2015; 57(2):186-91. PMC: 4738157. DOI: 10.2967/jnumed.115.161018. View

Cazaentre T, Clivaz F, Triponez F . False-positive result in 18F-fluorocholine PET/CT due to incidental and ectopic parathyroid hyperplasia. Clin Nucl Med. 2013; 39(6):e328-30. DOI: 10.1097/RLU.0b013e3182a77b62. View

Teunissen J, Kwekkeboom D, Valkema R, Krenning E . Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours. Endocr Relat Cancer. 2011; 18 Suppl 1:S27-51. DOI: 10.1530/ERC-10-0282. View

Cuccurullo V, Di Stasio G, Evangelista L, Castoria G, Mansi L . Biochemical and Pathophysiological Premises to Positron Emission Tomography With Choline Radiotracers. J Cell Physiol. 2016; 232(2):270-275. DOI: 10.1002/jcp.25478. View

Naswa N, Sharma P, Soundararajan R, Karunanithi S, Nazar A, Kumar R . Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings. Abdom Imaging. 2012; 38(3):552-60. DOI: 10.1007/s00261-012-9925-z. View

10.

Beheshti M, Pocher S, Vali R, Waldenberger P, Broinger G, Nader M . The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Eur Radiol. 2009; 19(6):1425-34. DOI: 10.1007/s00330-008-1280-7. View

11.

Bergenfelz A, Wallin G, Jansson S, Eriksson H, Martensson H, Christiansen P . Results of surgery for sporadic primary hyperparathyroidism in patients with preoperatively negative sestamibi scintigraphy and ultrasound. Langenbecks Arch Surg. 2010; 396(1):83-90. DOI: 10.1007/s00423-010-0724-0. View

12.

Bucau M, Laurent-Bellue A, Pote N, Hentic O, Cros J, Mikail N . 18F-FDG Uptake in Well-Differentiated Neuroendocrine Tumors Correlates with Both Ki-67 and VHL Pathway Inactivation. Neuroendocrinology. 2017; 106(3):274-282. DOI: 10.1159/000480239. View

13.

Grimaldi S, Young J, Kamenicky P, Hartl D, Terroir M, Leboulleux S . Challenging pre-surgical localization of hyperfunctioning parathyroid glands in primary hyperparathyroidism: the added value of F-Fluorocholine PET/CT. Eur J Nucl Med Mol Imaging. 2018; 45(10):1772-1780. DOI: 10.1007/s00259-018-4018-z. View

14.

Tabaksblat E, Langer S, Knigge U, Gronbaek H, Mortensen J, Petersen R . Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. Acta Oncol. 2015; 55(1):3-14. DOI: 10.3109/0284186X.2015.1067715. View

15.

Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R . Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol. 2011; 21(11):2408-16. DOI: 10.1007/s00330-011-2199-y. View

16.

Leboulleux S, Baudin E, Travagli J, Schlumberger M . Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004; 61(3):299-310. DOI: 10.1111/j.1365-2265.2004.02037.x. View

17.

Hoegerle S, Ghanem N, Altehoefer C, Schipper J, Brink I, Moser E . 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003; 30(5):689-94. DOI: 10.1007/s00259-003-1115-3. View

18.

Miljkovic M, Girotra M, Abraham R, Erlich R . Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci. 2011; 57(1):9-18. DOI: 10.1007/s10620-011-1854-0. View

19.

Anlauf M, Sipos B, Boeck I, Baldus S, Heikaus S, Krausch M . [Neuroendocrine neoplasms of the distal jejunum and ileum]. Pathologe. 2014; 35(3):283-93. DOI: 10.1007/s00292-013-1888-5. View

20.

Soussan M, Nataf V, Kerrou K, Grahek D, Pascal O, Talbot J . Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nucl Med Commun. 2012; 33(7):775-9. DOI: 10.1097/MNM.0b013e3283543304. View